<DOC>
	<DOCNO>NCT01021670</DOCNO>
	<brief_summary>The purpose study collect information regard safety dapoxetine hydrochloride use clinical practice treat men premature ejaculation . Dapoxetine hydrochloride selective inhibitor serotonin reuptake indicated treatment patient premature ejaculation .</brief_summary>
	<brief_title>An Observational Study Men With Premature Ejaculation Who Are Treated With Dapoxetine Hydrochloride Alternate Care Defined Any Treatment Other Than Dapoxetine Hydrochloride</brief_title>
	<detailed_description>This 12-week , observational study collect evaluate safety data dapoxetine hydrochloride alternate care/non-dapoxetine hydrochloride treatment ( ) define treatment ( eg , oral , topical , behavioral ) dapoxetine hydrochloride , recommend prescribe men diagnosis premature ejaculation . The primary objective study describe safety profile dapoxetine hydrochloride use clinical practice . The safety dapoxetine hydrochloride assess duing study monitor occurrence adverse event experience patient include adverse event special interest ( eg , syncope , characterize loss consciousness ) . Safety also assess monitor patient use concomitant medications/treatments include prescription medication , counter medication , vitamin herbal supplement , type therapy electrical stimulation , acupuncture , special diet , exercise regimen . Approximately 12,000 men premature ejaculation enrol study approximately 6,000 patient treated dapoxetine hydrochloride . All patient present practice evaluation premature ejaculation , diagnosis premature ejaculation currently treat consider enrollment study . All treatment decision make discretion participate health care provider . The study consist 3 period : pre-observational ( screening/baseline ) period ( Visit 1 ) , 12-week observational period ( Visits 2 , 3 , 4 ) , 4-week post-observational period . At Visit 1 , health care provider make confirm diagnosis premature ejaculation determine treatment dapoxetine hydrochloride alternate care/non-dapoxetine hydrochloride appropriate patient . There study-specific selection criterion guidance provide Summary Product Characteristics dapoxetine hydrochloride intend participate health care provider use Summary Product Characteristics dapoxetine hydrochloride guide identify appropriate patient study , type patient use caution avoid use dapoxetine hydrochloride . If healthcare provider determines patient candidate study , he/she explain detail study patient . Patients interested participate study willing able treat dapoxetine hydrochloride continue participate study long dapoxetine hydrochloride continue administer duration 12-week observational period , even situation topical and/or behavioral alternate care treatment add dapoxetine hydrochloride treatment regimen . Patients wish participate study ask sign date inform consent allow health care provider collect information require study . At Visit 1 , sign informed consent form obtain patient information collect include demographic ( example , patient 's race age ) , medical history include premature ejaculation history , physical examination finding , orthostatic vital sign ( blood pressure heart rate/pulse ) measurement . If health care provider determine patient treat dapoxetine hydrochloride , health care provider instruct patient administration dapoxetine hydrochloride accord dosage administration guideline Summary Product Characteristics dapoxetine hydrochloride follow : recommend start dose dapoxetine hydrochloride 30 mg , take without food least one full glass water approximately 1 3 hour prior prior sexual activity every 24 hour need . If effect dapoxetin hydrochloride dose 30 mg insufficient side effect acceptable , dose may increase maximum recommend dose 60 mg . If health care provider determine patient treated alternate care/non-dapoxetine hydrochloride treatment ( ) , health care provider instruct patient administration treatment prescribe direct . Following Visit 1 , patient participate 12-week observational period return 3 study visit ( Visits 2 , 3 , 4 ) accord health care provider 's local practice . At visit , health care provider evaluate dose dapoxetine hydrochloride alternate care/non-dapoxetine hydrochloride treatment ( ) need increase decreased information regard occurrence adverse event use concomitant medications/treatment collect . Approximately 4 week follow end 12-week observational period patient 's last visit study , health care provider contact patient telephone ass occurrence adverse event experience patient use concomitant medication treatment take since last study visit . Additional telephone contact patient may perform health care provider obtain additional information determine patient 's safety survival status . Regardless patient 's status end study ( ie , complete , discontinue treatment , withdraw early ) , patient receive dapoxetine hydrochloride ask complete survey provide feedback healthcare provider whether dapoxetine hydrochloride Patient Brochure and/or Patient Information Leaflet useful informative . Patients may participate study one time . Patients receive dapoxetine hydrochloride study enrol receive alternate care/non-dapoxetine hydrochloride treatment ( ) upon study completion discontinuation dapoxetine hydrochloride ) . The recommended starting dose dapoxetine hydrochloride 30 mg , take without food least 1 full glass water approximately 1 3 hour prior prior sexual activity every 24 hour need . Patients take dapoxetine hydrochloride 12 week observational period study . Alternate care/non dapoxetine hydrochloride treatment ( ) administer patient accordance prescribe information and/or direction use .</detailed_description>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Premature Ejaculation</mesh_term>
	<mesh_term>Sexual Dysfunction , Physiological</mesh_term>
	<criteria>In accordance therapeutic indication state Summary Product Characteristics dapoxetine hydrochloride , patient candidate enrollment intravaginal ejaculatory latency time le two minute Persistent recurrent ejaculation minimal sexual stimulation , , shortly penetration patient wish Marked personal distress interpersonal difficulty consequence premature ejaculation Poor control ejaculation In accordance contraindication , special warning precaution use state Summary Product Characteristics dapoxetine hydrochloride , patient exclude treatment hypersensitivity dapoxetine hydrochloride excipients Significant pathological cardiac condition : heart failure ( New York Heart Association [ NYHA ] class IIIV ) , conduction abnormality ( second third degree atrioventicular ( AV ) block sick sinus syndrome ) treat permanent pacemaker , significant ischemic heart disease , significant valvular disease Concomitant treatment monoamine oxidase inhibitor ( MAOIs ) , within 14 day discontinue treatment MAOI Concomitant treatment thioridazine , concomitant treatment serotonin reuptake inhibitor ( selective serotonin reuptake inhibitor [ SSRIs ] , serotoninnorepinephrine reuptake inhibitor [ SNRIs ] , tricyclic antidepressant [ TCAs ) ] medicinal/herbal product serotonergic effect ( example , Ltryptophan , triptans , tramadol , linezolid , lithium , St. John 's Wort ( Hypericum perforatum ) Concomitant treatment potent CYP3A4 inhibitor ketoconazole , itraconazole , ritonavir , saquinavir , telithromycin , nefazadone , nelfinavir , atazanavir , etc . Moderate severe hepatic impairment</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Dapoxetine hydrochloride</keyword>
	<keyword>Priligy</keyword>
	<keyword>Premature ejaculation</keyword>
	<keyword>Non-dapoxetine hydrochloride treatment ( )</keyword>
</DOC>